Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;14(7):1431-1441.
doi: 10.1002/1878-0261.12712. Epub 2020 Jun 22.

Role of radiation oncology in modern multidisciplinary cancer treatment

Vincenzo Valentini  1   2 , Luca Boldrini  1 , Silvia Mariani  2 , Mariangela Massaccesi  1
Affiliations
Review

Role of radiation oncology in modern multidisciplinary cancer treatment

Vincenzo Valentini et al. Mol Oncol. 2020 Jul.

Abstract

Cancer care is moving from a disease-focused management toward a patient-centered tailored approach. Multidisciplinary management that aims to define individual, optimal treatment strategies through shared decision making between healthcare professionals and patient is a fundamental aspect of high-quality cancer care and often includes radiation oncology. Advances in technology and radiobiological research allow to deliver ever more tailored radiation treatments in an ever easier and faster way, thus improving the efficacy, safety, and accessibility of radiation therapy. While these changes are improving quality of cancer care, they are also enormously increasing complexity of decision making, thus challenging the ability to deliver quality affordable cancer care. In this review, we provide an updated outline of the role of radiation oncology in the modern multidisciplinary treatment of cancer. Particularly, we focus on the way some developments in key areas of cancer management are challenging multidisciplinary cancer care in the different clinical settings of early, locally advanced, and metastatic disease, thus highlighting some priority areas of research.

Keywords: modern radiotherapy; multidisciplinary cancer treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M et al (2018) Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379, 2342–2350. - PubMed
    1. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TÅ, Tervonen H, Thursfield V, Ransom D, Shack L et al (2019) Progress in cancer survival, mortality, and incidence in seven high‐income countries 1995–2014 (ICBP SURVMARK‐2): a population‐based study. Lancet Oncol 20, 1493–1505. - PMC - PubMed
    1. Bai Y, Gao XS, Qin SB, Chen JY, Su MM, Liu Q, Qin XB, Ma MW, Zhao B, Gu XB et al (2018) Partial stereotactic ablative boost radiotherapy in bulky non‐small cell lung cancer: a retrospective study. Onco Targets Ther 11, 2571–2579. - PMC - PubMed
    1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JDF, Feuer EJ et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353, 1784–1792. - PubMed
    1. Bertuccio P, Alicandro G, Malvezzi M, Carioli G, Boffetta P, Levi F, La Vecchia C and Negri E (2019) Cancer mortality in Europe in 2015 and an overview of trends since 1990. Ann Oncol 30, 1356–1369. - PubMed